Orticumab

N/A

Report date: 2022/11/25 18:08:25

Base Information

Drug NameOrticumab
Drug Alias NameAnti-oxLDL奥替苏单抗Orticumabum奥替人单抗2D-03 +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionLDL cholesterol modulators
TargetsLDL cholesterol
Therapy Area/IndicationsInflammationPsoriasisAtherosclerosis +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBioinvent International Ab
China Registration ClassN/A

Develop Information

Active CompaniesChina Nt Pharma Group Company LtdAbcentra LLC
Inactive CompaniesBioinvent International AbGenentech Inc
Active IndicationsInflammationPsoriasisMyocardial Infarction +[7] 
Inactive IndicationsAtherosclerosis

Other Information

ATC CodeN/A
Related LinksWikipedia